Development pipeline of the Roche Group as of January 2026, by phase

© Statista 2026
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

January 2026

Region

Worldwide

Survey time period

January 29, 2026

Supplementary notes

Citation formats

Development pipeline of Roche Group 2026, by phase

Published by A. Minhas, Mar 3, 2026

As of January 2026, the Roche Group's development pipeline included ** new molecular entities (NMEs) and *** additional indications (AIs) in Phase I. Meanwhile, *** NME and *** AI were in the registration process for the United States and the European Union.

Log in or register to access precise data.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,399 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Roche "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Roche

Company positioning & scale

5

Financial scale & structure

4

Portfolio, segments & geography

6

R&D, pipeline & innovation

6

Competitive landscape

5

Outlook & risk

4

Further Content: You might find this interesting as well

Topics

RocheGlobal pharmaceutical industryJohnson & JohnsonNovartisCancer in the U.S.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

  • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,399 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.